What Ajax Health does

Ajax Health is a private medical device investment and operating firm founded in 2017 and headquartered in Menlo Park, California, with additional offices in New York City, Austin, and Los Angeles. The firm operates a proprietary "platform model" that builds dedicated, vertically focused entities to aggregate, develop, and commercialize medical device assets within specific therapeutic areas, combining startup agility with the strategic scale of industry partners. Ajax's operating portfolio includes Cordis and Cordis-X in cardiovascular, Maverix Medical, XII Medical, Protaryx Medical, Puzzle Medical, Endovascular Engineering, Cortica, Half Moon Medical, FlowMod, and Ladera Medical, alongside a joint venture with Hologic (lung cancer, formed November 2023) and a KKR-co-led heart-failure platform (formed March 2025), plus a strategic investment vehicle (Ajax Health Fund I) used for minority equity positions such as the $60M investment in France-based UroMems. The firm employs approximately 22 named professionals across Managing Partners, Operating Partners, SVPs in Finance/Legal/Medical/Operations, and engineering and commercial functions.

The firm's core technology is its turnkey operating methodology — combining capital, operating expertise, and creative deal structuring to build product portfolios faster than large incumbent medtech companies. Ajax generates returns through three streams: equity appreciation in portfolio companies monetized via strategic exits (Cortex → Boston Scientific, EPIX Therapeutics → Medtronic, Spirox → Entellus, CV Ingenuity → Covidien, FoxHollow → ev3/Medtronic), strategic minority investments from Ajax Health Fund I, and platform co-ownership and management participation fees. KKR is the lead institutional sponsor; Hellman & Friedman co-leads key affiliates. The firm is itself the subject of a pending acquisition by Eli Lilly for up to $2.3 billion announced on April 27, 2026.

Ajax primarily serves strategic partners in the medtech industry (Cordis, Hologic), institutional capital providers (KKR, Hellman & Friedman), repeat strategic acquirers (Boston Scientific, Medtronic), and ultimately clinicians and patients via the commercialized products of its portfolio companies (e.g., Ladera Large Bore Closure System, UroActive smart urology implant, FASTEN CE-mark program). The firm's GTM is enterprise-field-sales-style engagement with strategic partners rather than direct product distribution.

Name

Ajax Health

Legal name

Ajax Health Management Company, LLC

Website

https://ajaxhealth.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Ajax Health is a private medical device investment and operating firm that builds dedicated therapeutic-area platforms (Cordis, Maverix Medical, XII Medical, Cordis-X) and makes strategic equity investments to develop and commercialize healthcare assets, primarily serving strategic partners, institutional sponsors like KKR, and ultimately clinicians and patients.

Ownership category

akta.pro rank

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Investment returns / capital appreciation from portfolio company exits: Ajax generates returns through equity appreciation in portfolio companies, monetized via strategic exits and acquisitions (e.g., Cortex acquired by Boston Scientific; EPIX Therapeutics acquired by Medtronic; Spirox acquired by Entellus; CV Ingenuity acquired by Covidien; FoxHollow acquired by ev3/Medtronic). The firm is itself the subject of an acquisition by Eli Lilly for up to $2.3B.
2. Strategic equity investment in portfolio companies (UroMems $60M): Ajax Health Fund I makes strategic minority/strategic equity investments in growth-stage medtech companies (e.g., $60M into UroMems) generating returns through future liquidity events.
3. Platform co-ownership and management fees: Ajax builds dedicated platforms with industry leaders (Cordis, Hologic) and earns returns as co-owner/operator of these businesses, including management and operating participation fees.

Go-to-market motion1 record

Core offering

Ajax Health is a global medical device-focused investment firm and turnkey growth solution that partners with industry leaders to build and scale high-quality healthcare businesses. The firm deploys a proprietary platform model that creates dedicated, vertically focused operating platforms aggregating and developing medical device assets within specific therapeutic areas (cardiovascular, heart failure, lung cancer, urology), combining capital, operational expertise, and creative deal structuring. Revenue is generated through equity appreciation in portfolio companies, strategic investments via Ajax Health Fund I, and co-ownership/management of platform businesses.

Product overview

Ajax Health operates a platform-plus-affiliates architecture rather than a single unified product. At the center is Ajax Health itself — a global medical device-focused investment firm and turnkey growth solution that partners with industry leaders to build dedicated healthcare platforms. The core firm operates an investment vehicle (Ajax Health Fund I) and aggregates and develops medical device assets within specific therapeutic areas via a portfolio of affiliate/portfolio companies. These include cardiovascular platform Cordis-X (with the FASTEN trial for the Ladera Large Bore Closure System, developed in partnership with Ladera Medical), Maverix Medical, XII Medical, Puzzle Medical, Endovascular Engineering, Cortica, Protaryx Medical, and portfolio investment UroMems (UroActive System). Former affiliates include Cortex (acquired by Boston Scientific in November 2024) and FlowMod. Strategic partner platforms validating or extending the model include Cordis (cardiovascular, validating the model) and Hologic (joint venture for a new lung cancer division).

Differentiator

Problem solved

Functional benefit

Products and services

• Ajax Health Fund I

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• The Foundry: Medtech incubator and operating firm that creates, funds and operates dedicated device companies, then exits via strategic acquisition. Highly comparable to Ajax's platform-and-affiliates model, including Joe Koblish's prior tenure at The Foundry.
• HealthQuest Capital: Growth-stage healthcare investment firm that has co-invested alongside KKR in Ajax-affiliated rounds (per 2018–2019 funding rounds cited). Operates dedicated medtech platforms and is a directly comparable growth investor in the same therapeutic areas.
• Santé Ventures: Healthcare-focused venture firm that incubates and operates early- and growth-stage medtech companies with founder-operator involvement. Comparable to Ajax's hands-on model of building dedicated platform companies alongside management teams.
• Aisling Capital: Healthcare-dedicated investment firm where Managing Partner Aftab Kherani previously served as Partner. Direct historical relationship with Ajax's leadership and overlapping focus on medtech platforms.

Broad incumbents

• OrbiMed: One of the largest dedicated healthcare investment firms globally, investing across medtech, biopharma and diagnostics at venture, growth and buyout stages. Comparable as a medtech-focused investor/operator with multiple therapeutic-area platforms, though at materially larger fund size.
• KKR Health Care Strategic Growth: KKR's dedicated healthcare growth equity strategy, which is both Ajax's primary sponsor and a strategic investor in adjacent medtech assets. Functions as both a partner and a direct competitor for late-stage medtech deals.
• Sofinnova Partners: European-headquartered life sciences investment firm with a long-standing medtech franchise and dedicated therapeutic-area platforms. Comparable as a sector-specialist investor/operator with a track record of strategic exits in cardiovascular and structural heart.
• New Enterprise Associates (NEA) — Healthcare: Large diversified venture firm with a substantial healthcare practice investing across medtech and digital health. Competes with Ajax for growth-stage medtech deals and operating talent, though at much larger fund size.

Others

• Edwards Lifesciences: Large cardiovascular medical device incumbent operating in structural heart and critical care, where Ajax has prior relationships (e.g., VP of Engineering Neil Zimmerman was previously at Edwards). Strategic acquirer for many of the same therapeutic areas Ajax targets.
• Medtronic: Global medtech incumbent that has acquired multiple Ajax-affiliated or Rohlen-founded companies (CV Ingenuity via Covidien → Medtronic; EPIX Therapeutics; FoxHollow). Functions as a primary strategic acquirer in the same therapeutic areas where Ajax builds platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ajax_health?lang=en
• LinkedInlinkedin.com/company/ajaxhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries13 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments16 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ajax Health